Biogen acquires immunology start-up RayThera for $1bn
Anti-inflammatory assets in the deal allow Biogen to expand immunology pipeline into new disease areas.
Biogen is acquiring US biotech firm RayThera for up to $1 billion, through which it will obtain rights to a Phase I-ready lead asset, thus expanding its immunology pipeline.
As part of the acquisition, Biogen will access multiple anti-inflammatory assets for immune-mediated conditions across a range of indications.
The firm will handle the global development, manufacturing and global commercialisation of these assets…
Already a member? Sign-in
